Netherton Syndrome Clinical Trial
Official title:
A Randomized Double-blinded Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus. They may also use topical corticosteroids or calcineurin inhibitors in case of eczematous lesions. The use of therapies targeting skin inflammation has been reported in a few case reports. Their efficacy is very limited and their uses are limited because of the chronicity of the disease, the impaired skin barrier function and the risk for skin infections and skin cancers. Therefore, there is a huge medical need for novel therapies in NS.The expected consequences of this study are that a 16-week course of dupilumab will be more effective than placebo for the treatment of moderate to severe NS Dupilumab could therefore improve skin condition and quality of life.
This is a proof of concept (pilot) double-blind randomized placebo-controlled study evaluating the efficacy and safety of dupilumab for the treatment of NS. Patients will be randomized in a 2:1 ratio to receive dupilumab (2 doses of 300 mg), or placebo, at baseline and then 1 dose of dupilumab 300 mg, or placebo, every 2 weeks until week 14 (total of 8 administrations).Moderate to severe NS were selected in order to be able to measure the improvement of skin condition. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05979831 -
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT00208026 -
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT05583669 -
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01428297 -
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
|
Phase 1 | |
| Recruiting |
NCT05856526 -
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05789056 -
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05521438 -
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT05388903 -
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06137157 -
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
|
Phase 1 | |
| Not yet recruiting |
NCT05902663 -
Natural History of Netherton Syndrome
|
||
| Recruiting |
NCT03417856 -
Defining the Skin and Blood Biomarkers of Ichthyosis
|
||
| Completed |
NCT02113904 -
Clinical Trial Using Humira in Netherton Syndrome
|
Phase 2 | |
| Recruiting |
NCT05211830 -
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
| Recruiting |
NCT02081313 -
Natural History and Biological Study of Netherton Syndrome
|
N/A | |
| Recruiting |
NCT01545323 -
Gene Therapy for Netherton Syndrome
|
Phase 1 |